Top Industry Leaders in the Obesity Treatment Market
Latest Obesity Treatment Companies Update
August 2023: Novo Nordisk launches Wegovy (semaglutide), a new GLP-1 agonist medication showing substantial weight loss in clinical trials.
July 2023: Eli Lilly receives FDA approval for Mounjaro (tirzepatide), another GLP-1 agonist expected to offer similar weight-loss benefits.
December 2022: Vivus Therapeutics announces the commercial launch of Qsymia (phentermine/topiramate), a prescription weight-loss medication approved for long-term use.
September 2023: A Phase 3 trial begins for Rhythm Therapeutics' setmelanotide, a potential drug targeting appetite regulation in the hypothalamus.
August 2023: A study published in The New England Journal of Medicine suggests that intermittent fasting could be an effective weight-loss strategy.
July 2023: Researchers at the University of California, San Diego develop a new blood test that may predict individual responses to different weight-loss interventions.
- VIVUS, Inc. (U.S.)
- Arena Pharmaceuticals, Inc. (U.S.)
- Hoffmann-La Roche, Ltd. (Switzerland)
- Novo Nordisk A/S (Denmark)
- Orexigen Therapeutics, Inc. (U.S.)
- Allergan (Republic of Ireland)
- Cousin Biotech (France)
- EnteroMedics, Inc. (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- Medtronic (U.S.)
- USGI Medical, Inc. (U.S.)
- Mediflex Surgical Products (U.S.)
- Covidien plc (Republic of Ireland)
- Olympus Corporation (Japan)
- Takeda Pharmaceuticals Company Limited
- Eisai Co. Ltd.
- Novo Nordisk A/S
- Zafgen
- Rhythm Pharmaceuticals
- Zydus Cadila
- Norgine B.V.
- Vivus Therapeutics
- Arena Pharmaceuticals Inc.
- Orexigen Therapeutics Inc